Newly Published Study Demonstrates Clinical Utility of Daxor’s Blood Volume (BVA-100®) Diagnostic in the Assessment of Pos...
29 Abril 2021 - 9:31AM
Daxor Corporation (NYSE
MKT: DXR), the global leader in blood volume measurement
technology, today announces new data demonstrating the clinical
utility of the BVA-100 blood test in postural tachycardia syndrome
(POTS) published in the Journal of the American College of
Cardiology from the Vanderbilt Autonomic Dysfunction Center in
Nashville, TN.
The study titled “Effect of High Dietary Sodium
Intake in Patients with Postural Tachycardia Syndrome,” tested
whether high sodium diet reduces orthostatic tachycardia (heart
rate) and upright heart rate compared to low sodium diet in POTS
patients and secondary, its effect on plasma volume and plasma
norepinephrine. Blood volume parameters were measured with Daxor’s
BVA-100 diagnostic blood test; a safe, accurate and objective means
to directly quantify blood volume and composition. Blood volumes
were expressed as a percent deviation from the patient’s ideal
volumes.
The results showed that the mechanism of sodium
intake directly affects intravascular blood volume as measured by
the BVA-100 blood test. High dietary sodium compared to low dietary
sodium increases plasma volume and decreases the heart rate
supporting the recommendation to increase dietary sodium intake in
POTS.
“This study shows the crucial need to identify
and manage shifts in blood volume in order to guide optimal
treatment and outcomes in POTS patients. Daxor’s BVA-100 blood test
is the proven gold standard for doing so,” said Michael Feldschuh,
CEO and President of Daxor Corporation. “Prior studies have shown
marked heterogeneity in both total blood and red blood cell volume
- both prevalent in POTS.” About
Daxor Corporation
Daxor Corporation (NYSE: DXR) is the global
leader in blood volume measurement technology focused on blood
volume testing innovation (organized as an investment company with
fully-owned innovative medical instrumentation and biotechnology
operations). We developed and market the BVA-100® (Blood Volume
Analyzer), the first diagnostic blood test cleared by the FDA to
provide safe, accurate, objective quantification of blood volume
status and composition compared to patient-specific norms. The BVA
technology enhances hospital performance metrics in a broad range
of surgical and medical conditions, including heart failure and
critical care, by informing treatment strategies, resulting in
significantly improved multiple measures of patient outcomes.
Daxor's mission is to advance healthcare by enabling optimal fluid
management with blood volume analysis. Daxor’s vision is optimal
blood volume for all. For more information, please visit our
website at Daxor.com.
Forward-Looking
StatementsCertain statements in this release may include
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including without
limitation, statements regarding the impact of hiring sales staff
and expansion of our distribution channels. Forward-looking
statements are predictions, projections and other statements about
future events that are based on current expectations and
assumptions and, as a result, are subject to risks and
uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
release, including, without limitation, those risk associated with
our post-market clinical data collection activities, benefits of
our products to patients, our expectations with respect to product
development and commercialization efforts, our ability to increase
market and physician acceptance of our products, potentially
competitive product offerings, intellectual property protection,
FDA regulatory actions, our ability to integrate acquired
businesses, our expectations regarding anticipated synergies with
and benefits from acquired businesses, and additional other risks
and uncertainties described in our filings with the SEC.
Forward-looking statements speak only as of the date when made.
Daxor does not assume any obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise.
Investor Relations Contact:Bret
ShapiroSr. Managing Partner, CORE
IR516-222-2560brets@coreir.com
Daxor (AMEX:DXR)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Daxor (AMEX:DXR)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024